Published: 25 May 2018
Author(s): Roberta Joppi, Chiara Gerardi, Vittorio Bertele', Silvio Garattini
Issue: June 2018
Section: Original article

Pulmonary arterial hypertension (PAH) is a life-threatening rare disease. Between 2001 and 2016 the European Medicines Agency (EMA) approved nine drugs to treat PAH. Considering the poor prognosis of patients with PAH it would be useful to understand whether the approved therapies can change the natural history of the disease. We assessed the therapeutic value and the quality of the evidence on medicines that have been authorized by the EMA in the 2000s.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.